Lower Motor Neuron Facial Nerve Paralysis Following Recombinant Hepatitis B Vaccine Administration: A Case Report and Literature Review DOI Creative Commons

Raza Gulzar Ghouri,

Hamza Naeem, Mirza Rehan Yousaf

et al.

Clinical Case Reports, Journal Year: 2024, Volume and Issue: 12(12)

Published: Dec. 1, 2024

The Hepatitis B vaccine's safety profile is considered safe, but sometimes neurological complications, like Bell's palsy (acute peripheral facial neuropathy), can occur after its administration. A 35-year-old female doctor experienced left-sided weakness and paralysis six days getting the vaccine. On examination, she had lower motor neuron nerve palsy. After excluding other causes, a diagnosis of was made following She treated with corticosteroids, antiviral medication, physiotherapy, which led to complete resolution over four weeks. still an uncommon potential side effect even though advantages vaccination exceed risks. Further investigation necessary prove conclusive link between vaccine effects.

Language: Английский

Global burden of vaccine‐associated hepatobiliary and gastrointestinal adverse drug reactions, 1967–2023: A comprehensive analysis of the international pharmacovigilance database DOI
Sooji Lee, Kyeongmin Lee, Jaeyu Park

et al.

Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(7)

Published: July 1, 2024

Abstract Although previous studies have focused on hepatobiliary and gastrointestinal adverse drug reactions (ADRs) associated with COVID‐19 vaccines, literature such ADRs other vaccines is limited, particularly a global scale. Therefore, we aimed to investigate the burden of vaccine‐associated identify implicated in these occurrences. This study utilized data from World Health Organization (WHO) international pharmacovigilance database extract reports 1967 2023 (total = 131 255 418). Through reporting counts, reported odds ratios (ROR) 95% confidence interval (CI), information components (IC) IC 0.25 , examined association between 16 incidence across 156 countries. Of 6 842 303 ADRs, 10 786 liver injury, 927 870 symptoms, 2978 pancreas bile duct 96 intra‐abdominal hemorrhage were identified. Most surged after 2020, majority attributed messenger RNA (mRNA) vaccines. Hepatitis A exhibited highest injury (ROR [95% CI]: 10.30 [9.65–10.99]; [IC ]: 3.33 [3.22]), followed by hepatitis B, typhoid, rotavirus. Specifically, ischemic had significant both Ad5‐vectored mRNA Gastrointestinal symptoms all except for tuberculosis rotavirus (11.62 [11.45–11.80]; 3.05 [3.03]) typhoid (11.02 [10.66–11.39]; 3.00 [2.96]). Pancreas (1.99 [1.89–2.09]; 0.90 [0.83]), MMR (measles, mumps, rubella), papillomavirus For hemorrhage, inactivated whole‐virus (3.93 [1.86–8.27]; 1.71 [0.41]) association, (1.81 [1.42–2.29]; 0.77 [0.39]). short time onset, within 1 day, low mortality rate. scale database, occurred emphasizing importance healthcare workers' vigilant monitoring timely management.

Language: Английский

Citations

11
Analytical review of facial nerve palsy following SARS-CoV-2 vaccination: comprehensive assessment DOI Creative Commons
Ahmad A. Mirza, Abdulaziz H. Almalki, Zaid Almubarak

et al.

European Archives of Oto-Rhino-Laryngology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

Language: Английский

Citations

1
Global Burden of Drug‐Induced Severe Cutaneous Adverse Reactions Associated With 33 Classes of Antibiotics (1968–2024): An Analysis of International Pharmacovigilance Reports DOI
Jaehyun Kong, Jeongseon Oh, Jaeyu Park

et al.

Clinical & Experimental Allergy, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Language: Английский

Citations

0
Post COVID-19 and Long COVID Symptoms in Otorhinolaryngology—A Narrative Review DOI Open Access
Orlando Guntinas‐Lichius,

Thomas Bitter,

Robert P. Takes

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(2), P. 506 - 506

Published: Jan. 14, 2025

Post/Long COVID (syndrome) is defined as a condition with symptoms persisting for more than 12 weeks after the onset of SARS-CoV-2 infection that cannot be explained otherwise. The prevalence self-reported otorhinolaryngological high. aim this review was to analyze current literature regarding actual prevalence, knowledge etiopathology, and evidence-based treatment recommendations otorhinolaryngology-related symptoms. A systematic search articles published since 2019 in PubMed ScienceDirect performed resulted 108 articles. These were basis formed comprehensive series consented therapy statements on most important Otorhinolaryngological did not appear isolated but part multi-organ syndrome. Self-reported often confirmed by objective testing. estimated anosmia, dysgeusia, cough, facial palsy, hoarseness/dysphonia, acute hearing loss, tinnitus, vertigo/dizziness about 4%, 2%, 4-19%, 0%, 17-20%, 8%, 20%, 5-26%, respectively. There are manifold theoretical concepts etiopathology different symptoms, there no clear proof. This certainly contributes fact effective specific option any mentioned. Healthcare pathways must established so can recognized evaluated otorhinolaryngologists provide counseling. would also help establish selectively include patients clinical trials investigating therapeutic concepts.

Language: Английский

Citations

0
Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023 DOI Creative Commons
Soo‐Young Yoon, Sooji Lee, Kyeongmin Lee

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: July 12, 2024

Abstract This study aims to figure out the worldwide prevalence of anticancer therapy-associated acute kidney injury (AKI) and tubulointerstitial nephritis (TIN) relative risk each cancer drug. We conducted an analysis VigiBase, World Health Organization pharmacovigilance database, 1967–2023 via disproportionate Bayesian reporting method. further categorized drugs into four groups: cytotoxic therapy, hormone immunotherapy, targeted therapy. Reporting odds ratio (ROR) information component (IC) compares observed expected values investigate associations category with AKI TIN. identified 32,722 2056 reports (male, n = 17,829 1,293) TIN, respectively, among 4,592,036 all-drug caused There has been a significant increase in since 2010, primarily due increased therapy immunotherapy. Immunotherapy exhibited association both (ROR: 8.92; IC 0.25 : 3.06) TIN (21.74; 4.24), followed by (7.14; 2.68), (5.83; 2.40), (2.59; 1.24) for AKI, (2.60; 1.21) (1.54; 0.61) were more prevalent individuals under 45 years age, female preponderance males These events reported close temporal relationship after initiation respective drug (16.53 days 27.97 TIN), high fatality rate, 23.6% 16.3% findings underscore that kidney-related adverse reactions are prognostic significance strategies mitigate such side effects required optimize

Language: Английский

Citations

3
Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 DOI Creative Commons

Yi Deun Jeong,

Seoyoung Park, Sooji Lee

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Oct. 19, 2024

Research on Guillain-Barré syndrome (GBS) as a neurological adverse effect of vaccines global scale is scarce, highlighting the need for further investigation to evaluate its long-term impact and associated risk factors comprehensively. Hence, this study aims assess burden vaccine-associated GBS vaccines. This utilized data from VigiBase, World Health Organization database event reports medicines vaccines, encompassing period 1967 2023 (total reports, n = 131,255,418) investigate GBS. Reported odds ratios (ROR) information components (IC) were analyzed association between 19 occurrence over 170 countries. We identified 15,377 (8072 males [52.49%]) among 22,616 all drugs-cause 1978 2023. Cumulative have been increasing steadily time, with notable surge observed since commencement COVID-19 administration in 2020. Most showed significant associations such Ad5-vectored (ROR, 14.88; IC, 3.66), mRNA 9.66; 2.84), inactivated whole-virus 3,29; IC 1.69). Influenza highest 77.91; 5.98). Regarding age-and sex-specific risks, remained similar regardless sex, an increased advancing age. The mean time onset was 5.5 days. Amid pandemic, surged response widespread vaccination. Nonetheless, exhibited lowest compared other Vigilance at least one-week post-vaccination crucial, particularly older adults. Further research warranted elucidate underlying mechanisms linking

Language: Английский

Citations

2
Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study DOI Creative Commons

Yi Deun Jeong,

Hyesu Jo,

Hanseul Cho

et al.

International Archives of Allergy and Immunology, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 15

Published: Dec. 3, 2024

Introduction: The safety of biologics, other than TNF-α inhibitors, during pregnancy has not been sufficiently established. To assess the risk pregnancy-related adverse outcomes biologics used for psoriasis, compared to we utilized WHO global pharmacovigilance database (1968–2024). Methods: We World Health Organization’s from 1968 2024. From over 140 million reports more 170 countries, extracted 6,518 associated with interest. These included inhibitors (e.g., etanercept, infliximab, adalimumab, certolizumab pegol), IL-12/IL-23 inhibitor ustekinumab), IL-17 secukinumab, brodalumab, ixekizumab, bimekizumab), and IL-23 guselkumab, tildrakizumab, risankizumab). Each biologic was pegol in two separate disproportionality analyses. reporting odds ratio (ROR) calculated maternal, fetal, neonatal outcomes, categorized into seven major groups. Multivariable sensitivity analyses were conducted validate primary results. Results: analysis showed that, most had a lower frequency exception brodalumab. Specifically, ROR 95% confidence intervals (CIs) as follows: ustekinumab (ROR, 0.27; CI: 0.21–0.35), secukinumab (0.17; 0.13–0.22), brodalumab (0.20; 0.02–2.21), ixekizumab (0.05; 0.03–0.08), bimekizumab (0.10; 0.01–0.71), guselkumab (0.09; 0.05–0.15), tildrakizumab (0.02; 0.00–0.14), risankizumab (0.38; 0.25–0.58). However, reported higher abortion stillbirth (1.87; 1.32–2.63). findings consistent when pegol, well multivariable Furthermore, comparing infliximab 0.71; 0.55–0.92), etanercept comparable (1.00; 0.77–1.31), adalimumab (1.42; 1.11–1.81). Conclusions: Biologics exhibit suggesting their potential be safe options pregnancy. further studies are necessary evaluate these pregnancy, accounting confounding factors.

Language: Английский

Citations

2
Lower Motor Neuron Facial Nerve Paralysis Following Recombinant Hepatitis B Vaccine Administration: A Case Report and Literature Review DOI Creative Commons

Raza Gulzar Ghouri,

Hamza Naeem, Mirza Rehan Yousaf

et al.

Clinical Case Reports, Journal Year: 2024, Volume and Issue: 12(12)

Published: Dec. 1, 2024

The Hepatitis B vaccine's safety profile is considered safe, but sometimes neurological complications, like Bell's palsy (acute peripheral facial neuropathy), can occur after its administration. A 35-year-old female doctor experienced left-sided weakness and paralysis six days getting the vaccine. On examination, she had lower motor neuron nerve palsy. After excluding other causes, a diagnosis of was made following She treated with corticosteroids, antiviral medication, physiotherapy, which led to complete resolution over four weeks. still an uncommon potential side effect even though advantages vaccination exceed risks. Further investigation necessary prove conclusive link between vaccine effects.

Language: Английский

Citations

1